Press Releases

Business & Solutions

Validation de la performance des tests sérologiques VIDAS® de bioMérieux pour le SARS-CoV-2 avant un lancement imminent

bioMérieux, acteur majeur dans le domaine du diagnostic in vitro, annonce la validation de la performance et le lancement prochain des tests sérologiques VIDAS® anti-SARS-CoV-2 pour la détection des a...

BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains FDA Emergency Use Authorization

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in syndromic infectious disease testing, has received Emergency Us...

First-Quarter 2020 Business Review

bioMérieux fully mobilized against COVID-19 epidemic Organic growth of more than 20% at constant exchange rates and scope of consolidation over the first quarter: €769 million in sales Up 21.5% as rep...

bioMérieux’s Annual General Meeting postponed

Due to the unprecedented circumstances linked to the COVID-19 pandemic, the Board of Directors of bioMérieux, which met today, has decided to postpone the Annual General Meeting initially scheduled on...

bioMérieux receives Emergency Use Authorization for BIOFIRE® COVID-19 test

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that its subsidiary, BioFire Defense, has received Emergency Use Authorization by the U.S. Food and Drug Administration...

First of 3 diagnostic tests for SARS-CoV-2 coronavirus available from bioMérieux

bioMérieux, a world leader in the field of in vitro diagnostics, is announcing the forthcoming launch of 3 different tests to address the COVID-19 epidemic and to meet the different needs of physician...